- Home
- MLYS vs HSII Comparison
MLYS vs HSII Comparison
Compare MLYS & HSII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- HSII
- Stock Information
- Founded
- MLYS 2019
- HSII 1953
- Country
- MLYS United States
- HSII United States
- Employees
- MLYS N/A
- HSII N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- HSII Diversified Commercial Services
- Sector
- MLYS Health Care
- HSII Consumer Discretionary
- Exchange
- MLYS Nasdaq
- HSII Nasdaq
- Market Cap
- MLYS 1.0B
- HSII 904.6M
- IPO Year
- MLYS 2023
- HSII 1999
- Fundamental
- Price
- MLYS $13.48
- HSII $42.76
- Analyst Decision
- MLYS Strong Buy
- HSII Buy
- Analyst Count
- MLYS 4
- HSII 2
- Target Price
- MLYS $27.00
- HSII $49.00
- AVG Volume (30 Days)
- MLYS 667.1K
- HSII 107.7K
- Earning Date
- MLYS 08-12-2025
- HSII 07-28-2025
- Dividend Yield
- MLYS N/A
- HSII 1.41%
- EPS Growth
- MLYS N/A
- HSII N/A
- EPS
- MLYS N/A
- HSII 0.37
- Revenue
- MLYS N/A
- HSII $1,116,954,000.00
- Revenue This Year
- MLYS N/A
- HSII $6.41
- Revenue Next Year
- MLYS N/A
- HSII $2.65
- P/E Ratio
- MLYS N/A
- HSII $115.91
- Revenue Growth
- MLYS N/A
- HSII 6.10
- 52 Week Low
- MLYS $8.24
- HSII $30.20
- 52 Week High
- MLYS $18.38
- HSII $49.02
- Technical
- Relative Strength Index (RSI)
- MLYS 35.32
- HSII 45.73
- Support Level
- MLYS $12.98
- HSII $42.86
- Resistance Level
- MLYS $16.67
- HSII $44.14
- Average True Range (ATR)
- MLYS 0.81
- HSII 0.81
- MACD
- MLYS -0.33
- HSII -0.22
- Stochastic Oscillator
- MLYS 13.56
- HSII 21.03
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
About HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments include the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.